Citius Pharmaceuticals, Inc. (CTXR) Financial Statements (2024 and earlier)

Company Profile

Business Address 11 COMMERCE DRIVE
CRANFORD, NJ 07016
State of Incorp. NV
Fiscal Year End September 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
Q4
6/30/2023
Q3
3/31/2023
Q2
12/31/2022
Q1
9/30/2022
Q4
6/30/2022
Q3
3/31/2022
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments33,281,83029,065,52236,887,25141,711,69048,044,19455,756,232
Cash and cash equivalents33,281,83029,065,52236,887,25141,711,69048,044,19455,756,232
Prepaid expense7,832,3205,835,6025,430,1252,852,5802,790,3192,503,109
Total current assets:41,114,15034,901,12442,317,37644,564,27050,834,51358,259,341
Noncurrent Assets
Operating lease, right-of-use asset503,817552,205599,617646,074691,593736,209
Property, plant and equipment2,0102,6393,3704,1004,8315,562
Intangible assets, net (including goodwill)9,346,7969,346,7969,346,7969,346,7969,346,7969,346,796
Goodwill9,346,7969,346,7969,346,7969,346,7969,346,7969,346,796
Other undisclosed noncurrent assets59,438,06259,438,06259,438,06259,438,06259,438,06259,438,062
Total noncurrent assets:69,290,68569,339,70269,387,84569,435,03269,481,28269,526,629
TOTAL ASSETS:110,404,835104,240,826111,705,221113,999,302120,315,795127,785,970
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,972,5414,976,4294,334,9944,333,0234,269,2203,835,007
Employee-related liabilities2,107,0141,762,2511,277,501793,250
Accounts payable3,079,6672,725,5931,537,5781,165,3781,690,5201,705,128
Accrued liabilities892,8742,250,836690,4021,405,3941,301,1991,336,629
Other undisclosed current liabilities1,818,3161,233,248202,178196,989191,902186,916
Total current liabilities:5,790,8576,209,6774,537,1724,530,0124,461,1224,021,923
Noncurrent Liabilities
Long-term debt and lease obligation:    481,245532,883582,302
Liabilities, other than long-term debt6,313,8116,224,6316,134,3685,561,8004,985,8004,985,800
Deferred income tax liabilities5,993,8005,849,8005,705,8005,561,8004,985,8004,985,800
Operating lease, liability320,011374,831428,568481,245532,883582,302
Total noncurrent liabilities:6,313,8116,224,6316,134,3686,043,0455,518,6835,568,102
Total liabilities:12,104,66812,434,30810,671,54010,573,0579,979,8059,590,025
Equity
Equity, attributable to parent97,699,78791,206,138100,433,301102,825,865109,735,610117,595,565
Common stock158,858146,358146,211146,211146,129146,129
Additional paid in capital249,828,398234,867,917233,569,202232,368,121231,287,208230,283,531
Accumulated deficit(152,287,469)(143,808,137)(133,282,112)(129,688,467)(121,697,727)(112,834,095)
Equity, attributable to noncontrolling interest600,380600,380600,380600,380600,380600,380
Total equity:98,300,16791,806,518101,033,681103,426,245110,335,990118,195,945
TOTAL LIABILITIES AND EQUITY:110,404,835104,240,826111,705,221113,999,302120,315,795127,785,970

Income Statement (P&L) (USD)

9/30/2023
Q4
6/30/2023
Q3
3/31/2023
Q2
12/31/2022
Q1
9/30/2022
Q4
6/30/2022
Q3
3/31/2022
Q2
Operating expenses(8,672,112)(10,685,300)(7,249,883)(7,549,566)(8,916,652)(7,590,625)
Operating loss:(8,672,112)(10,685,300)(7,249,883)(7,549,566)(8,916,652)(7,590,625)
Nonoperating income336,780303,275214,549134,82653,02029,571
Investment income, nonoperating 336,780303,275214,549134,82653,02029,571
Interest and debt expense   3,585,689   
Other undisclosed loss from continuing operations before equity method investments, income taxes      
Loss from continuing operations before income taxes:(8,335,332)(10,382,025)(3,449,645)(7,414,740)(8,863,632)(7,561,054)
Income tax expense(144,000)(144,000)(144,000)   
Other undisclosed loss from continuing operations    (576,000)  
Loss from continuing operations:(8,479,332)(10,526,025)(3,593,645)(7,990,740)(8,863,632)(7,561,054)
Loss before gain (loss) on sale of properties:(7,990,740)(8,863,632)(7,561,054)
Income from discontinued operations   3,585,689   
Other undisclosed net loss   (3,585,689)   
Net loss attributable to parent:(8,479,332)(10,526,025)(3,593,645)(7,990,740)(8,863,632)(7,561,054)
Other undisclosed net loss available to common stockholders, basic      
Net loss available to common stockholders, diluted:(8,479,332)(10,526,025)(3,593,645)(7,990,740)(8,863,632)(7,561,054)

Comprehensive Income (USD)

9/30/2023
Q4
6/30/2023
Q3
3/31/2023
Q2
12/31/2022
Q1
9/30/2022
Q4
6/30/2022
Q3
3/31/2022
Q2
Net loss:(8,479,332)(10,526,025)(3,593,645)(7,990,740)(8,863,632)(7,561,054)
Comprehensive loss, net of tax, attributable to parent:(8,479,332)(10,526,025)(3,593,645)(7,990,740)(8,863,632)(7,561,054)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: